Quantcast
Home > Quotes > AST

Asterias Biotherapeutics, Inc. Common Series A (AST) Quote & Summary Data

AST 
$0.89
*  
0.01
1.11%
Get AST Alerts
*Delayed - data as of Dec. 11, 2018  -  Find a broker to begin trading AST now
Exchange:AMEX
Industry: Health Care
Community Rating:
View:    AST Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
6
Today's High / Low
$ 0.98 / $ 0.89
Share Volume
21,523
90 Day Avg. Daily Volume
183,020
Previous Close
$ 0.90
52 Week High / Low
$ 2.65 / $ 0.7601
Market Cap
49,536,229
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.74

Intraday Chart

Shares Traded

Share Volume:
21,523
90 Day Avg. Daily Volume:
183,020

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.37

Trading Range

The current last sale of $0.89 is 17.09% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.98 $ 2.65
 Low: $ 0.89 $ 0.7601

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer. We have industry-leading technology in two cell types, each with broad potential applicability: (1) oligodendrocyte progenitor cells, which become oligodendrocytes that have the potential to remyelinate axons within the central nervous system and perform other restorative functions, and (2) antigen-presenting dendritic cells, which train T-cells in the immune system to attack and destroy solid or liquid tumor cells across multiple types of cancer.  ... More ...  


Risk Grade

Where does AST fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info